18000564. STEM-CELL BASED BIOMARKER DISCOVERY simplified abstract (The Regents of the University of California)
Contents
- 1 STEM-CELL BASED BIOMARKER DISCOVERY
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 STEM-CELL BASED BIOMARKER DISCOVERY - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
STEM-CELL BASED BIOMARKER DISCOVERY
Organization Name
The Regents of the University of California
Inventor(s)
Mathew Blurton-jones of Irvine CA (US)
Jean Paul Chadarevian of Irvine CA (US)
Robert Spitale of Irvine CA (US)
Sunil Gandhi of Irvine CA (US)
STEM-CELL BASED BIOMARKER DISCOVERY - A simplified explanation of the abstract
This abstract first appeared for US patent application 18000564 titled 'STEM-CELL BASED BIOMARKER DISCOVERY
Simplified Explanation
The present invention involves the development and use of genetically modified human cells combined with xenotransplantation into animal models to identify injury and disease-specific RNA and/or protein biomarkers. Two methods are described for biomarker discovery, allowing for the isolation and analysis of human-specific RNA and proteins from animal models treated with RNA and amino acid analogs.
- Genetically modified human cells are used in combination with xenotransplantation into animal models.
- Two methods for biomarker discovery are described, involving the treatment of animal models with RNA and amino acid analogs.
- These methods enable the specific isolation and quantification of human RNAs and proteins for the identification of novel biomarkers for various human injuries and diseases.
Potential Applications
The technology could be applied in the fields of personalized medicine, drug development, and disease diagnosis.
Problems Solved
This technology allows for the identification of injury and disease-specific biomarkers, which can lead to earlier detection and more targeted treatment options.
Benefits
The technology enables the direct and selective labeling, isolation, and analysis of human-specific RNA and proteins, providing valuable insights into human injuries and diseases.
Potential Commercial Applications
The technology could be utilized in pharmaceutical companies, research institutions, and diagnostic laboratories for biomarker discovery and development of new therapies.
Possible Prior Art
One possible prior art could be the use of animal models for biomarker discovery, but the specific methods described in this invention involving genetically modified human cells and RNA/analog treatment are novel and innovative.
Unanswered Questions
1. How scalable is the process of isolating and quantifying human-specific RNA and proteins using this technology? 2. What are the potential ethical considerations surrounding the use of genetically modified human cells in animal models for biomarker discovery?
Original Abstract Submitted
The present invention relates to the development of and use of genetically modified human differentiated cells coupled with xenotransplantation into animal models to identify injury and disease-specific RNA and/or protein biomarkers. Specifically, the present invention encompasses two complementary methods for biomarker discovery that enable the direct and selective labelling, isolation, and analysis of human-specific RNA and/or proteins from xenotransplantation (or chimeric) animal models. Both methods involve the treatment of animal models with an RNA analog and/or amino acid analog that enables the specific isolation and quantification of human RNAs and/or proteins for the identification of novel human biomarkers for a large array of human injuries and diseases.
